Direxion Daily NVDA Bear 1X Shares (NVDD)
- Previous Close
7.34 - Open
7.53 - Bid 7.33 x 51000
- Ask 7.36 x 50000
- Day's Range
7.34 - 7.53 - 52 Week Range
6.98 - 28.21 - Volume
2,621,024 - Avg. Volume
2,594,095 - Net Assets 28.63M
- NAV 7.34
- PE Ratio (TTM) --
- Yield --
- YTD Daily Total Return -66.06%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 1.01%
The fund, under normal circumstances, invests at least 80% of the it’s net assets (plus borrowings for investment purposes) in financial instruments, including swap agreements and options, that, in combination, provide 1X daily inverse (opposite) or short exposure to NVDA, consistent with the fund’s investment objective. The fund is non-diversified.
Direxion Funds
Fund Family
Trading--Inverse Equity
Fund Category
28.63M
Net Assets
2023-09-12
Inception Date
Performance Overview: NVDD
View MoreTrailing returns as of 9/27/2024. Category is Trading--Inverse Equity.
People Also Watch
Research Reports: NVDD
View MoreRaising target price to $185.00
ICU MEDICAL INC has an Investment Rating of HOLD; a target price of $185.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $174.00
ICU MEDICAL INC has an Investment Rating of HOLD; a target price of $174.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $172.00
ICU MEDICAL INC has an Investment Rating of HOLD; a target price of $172.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetLivaNova Earnings: Strong Execution and New Product Cycle Support Outperformance
UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
RatingPrice Target